CDK4 and breast cancer: Collectively preclinical and clinical data demonstrate that combined targeting of either ER inhibitors with CDK4/6 inhibitors (palbociclib, abemaciclib or ribociclib) or ER inhibitors with inhibitors of PI3K, mTORC1 or AKT gives benefit in patients with metastatic ER+BC.